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Introduction: Although autogenous brachial-basilic upper arm transpositions (BVT) have been extensively utilized, there
has been significant disparity in published patency rates. Very little is known about the efficacy of autogenous
brachial-cephalic upper arm transpositions (CVT).We evaluated our experience with transposed upper arm arteriovenous
fistulas (tAVF) in order to assess patency and identify factors that affect efficacy. We then compared our tAVF patients
with a cohort of upper arm arteriovenous grafts (AVG).
Methods:A retrospective review was conducted of tAVF performed at our institution from 1998 to 2004. The tAVF group
consisted of 119 BVT and 71 CVT procedures. We compared these with 164 AVG. tAVF were placed only for veins>2.5
mm in diameter by duplex ultrasonography.
Results: Mean follow-up was 28 months. With the exception of mean vein diameter, the patients in the BVT and CVT
groups had similar demographic parameters and complication rates. Primary and secondary patency rates were 52% and
62% at 5 years for BVT and 40% and 46% at 5 years for CVT, respectively (P  NS). Multivariate analysis revealed that
hemodialysis dependence at the time of fistula placement and history of previous upper arm access independently affected
primary patency. History of upper torso dialysis catheters independently affected secondary patency. Comparison of the
tAVF and AVG groups revealed that tAVF patients were significantly younger, more likely to be male, less likely to be
African American (AA) and less likely to have a history of previous AV access. The primary patency rate for tAVF was
significantly higher than for AVG: 48% vs 14% at 5 years (P < .001). The secondary patency rate for tAVF was also
significantly higher than for AVG: 57% vs 17% at 5 years (P < .001). Among the tAVF procedures, 9% required one or
more revisions to maintain secondary patency, compared to 51% with the AVG group (P < .001). Multivariate analysis
revealed that presence of AVG and a history of previous upper arm access negatively affected primary and secondary
patency.
Conclusions: Autogenous BVT and CVT have similar, high patency rates. Transposed upper arm arteriovenous fistulas
have higher patency rates than upper arm AVG and require significantly fewer revisions. Our data strongly support the
contention that as long as the patient is a candidate for an upper arm tAVF, based on anatomical criteria, a tAVF should
always be considered before an AVG. (J Vasc Surg 2007;46:94-101.)End-stage renal disease (ESRD) is a significant public
health problem in the United States.1 During the past
decade, increasing prevalence of patients requiring hemo-
dialysis 2 has resulted in dialysis access procedures becom-
ing some of the most common operations performed by
vascular surgeons. Long-term hemodialysis access includes
native arteriovenous fistulas (AVF) and prosthetic arterio-
venous grafts (AVG). In the mid 1990s, only 20% of
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94patients in the United States were dialyzing with native
AVF.3 Because of data illustrating superior patency of
native AVF, the National Kidney Foundation Dialysis Out-
come and Quality Initiative (DOQI) recommended, that
native AVF should be constructed in at least 50% of perma-
nent hemodialysis access procedures.4-6 The recently cre-
ated Fistula First Initiative further encourages use of native
AVF by providing physicians with an algorithm designed to
optimize care of patients with ESRD.7 Despite these rec-
ommendations, native AVF use was only 36% in 2004.7
Increasing age and complexity of patients with ESRD
has commonly been associated with clinical scenarios where
wrist or simple antecubital AVF construction is not possi-
ble. Upper arm transposed AVF (tAVF) such as autogenous
brachial-basilic upper arm transposition (BVT) have been
described in patients who are not candidates for forearm
native AVF.8 There are a number of reports describing
excellent patency of BVT.9-13 However, some studies re-
port equivocal results.14,15 Autogenous brachial-cephalic
upper arm transposition (CVT) AVF has been described
but their utility and efficacy have not been well defined
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tion is not necessary.16 Also, simple brachiocephalic fistulas
are often performed without concern for vein depth since
some surgeons rely on secondary fistula elevation proce-
dures.13,17 In order to avoid difficulties with fistula access
and secondary fistula elevation procedures, we were liberal
to transpose the cephalic vein when it was not superficial.
We evaluated our extensive experience with upper arm
BVT and CVT procedures in order to assess and compare
patency rates, as well as to determine factors that affect
efficacy. We then combined our BVT and CVT patients
into a tAVF group and compared it with a cohort of upper
arm AVG.
METHODS
We retrospectively evaluated upper arm tAVF per-
formed at Cedars-Sinai Medical Center in Los Angeles,
California between January 1998 and September 2004.
The fistula group consisted of consecutive upper arm BVT
and CVT procedures. This tAVF group included patients
who had previous access construction in the ipsilateral as
well as the contralateral upper extremity.
A comparison AVG cohort was selected from a group
of procedures chosen from the middle of our study period.
Only primary upper armAVGwere included for evaluation;
there were no previous access procedures performed in the
ipsilateral upper extremity of the AVG patients. Some AVG
patients did have previous access procedures performed in
the contralateral upper extremity.
Office, hospital, and electronic charts were reviewed
after Institutional Review Board exemption status was
granted. Comorbid conditions were noted and graded
according to the recommended reporting standards.18 Di-
alysis dependence at the time of AVF placement and history
of upper torso (subclavian or jugular) dialysis catheters
were recorded.
All patients underwent preoperative noninvasive vascu-
lar evaluation that included brachial pressures and wave-
forms, Allen’s test, and brachial/radial artery diameter
measurements. Vein mapping was routinely performed to
outline and define the size and quality of basilic and ce-
phalic veins. Vein diameter was recorded and the mean vein
diameter was calculated for tAVF patients.
In our practice, we attempted to first place a wrist
radiocephalic fistula if anatomically favorable. From there,
we moved to a simple brachiocephalic fistula at the antecu-
bital fossa. If this was not feasible, we placed either an upper
arm AVG or an upper arm tAVF. The forearm transposed
fistula or loop graft was rarely used.
The decision to construct an upper arm tAVF was
based, in general, on the presence of adequate arterial
inflow into the arm, upper arm vein diameter2.5 mm and
absence of suitable forearm site for an autogenous fistula. If
upper arm cephalic vein was judged adequate on duplex
evaluation and superficial on tourniquet-aided examination
by the surgeon, an antecubital nontransposed brachioce-
phalic fistula was constructed. Otherwise, either an upper
arm BVT or CVT was placed. The larger of the two upperarm veins, as measured by duplex, was used preferentially.
We were liberal to transpose the cephalic vein if it was not
easily palpable on tourniquet-assisted physical examination.
Patients who were not judged to be candidates for a native
AV fistula were treated with upper arm, straight configura-
tion, 6 mm polytetrafluoroethylene (PTFE) AV grafts (WL
Gore and Associates Inc, Phoenix, Ariz, and Bard Inc,
Tempe, Ariz). No looped arm, forearm, or tapered AVG
were utilized. Ultimately, the decision of type of access was
determined by surgeon preference.
Operative details are described in Appendix I (online
only).
Perioperative and postoperative complications were
followed by the operative surgeon. Complications were
graded according to the recommended standards for re-
ports dealing with arteriovenous hemodialysis access pro-
cedures. The complications that followed were grade 2
wound infection (requiring operative exploration or re-
moval of access), grade 3 (severe) steal (requiring manda-
tory intervention), grade 3 postoperative hemorrhage (ne-
cessitating return to the operating room), and fistula
thrombosis within 24 hours.18 Grade 3 steal was treated
either with fistula banding or the distal revascularization
interval ligation procedure. Thirty-day mortality rate was
calculated.
A follow-up visit with the vascular surgeon was sched-
uled during the first month after discharge for suture
removal and at that time fistula patency was assessed by
physical examination. Transposed AVF were allowed to
mature for aminimumof 8 weeks, and the decision when to
use the access for the first time was made either by the
attending surgeon or nephrologist. Grafts were typically
accessed for dialysis 10 to 14 days after implantation.
No routine surveillance was performed. Noninvasive
imaging was used in the initial evaluation of a malfunction-
ing access. A fistulagram was performed only when symp-
tomatic fistula or graft stenosis were suspected. This was
done when intra-access flowwas less than 600mL/min and
static or dynamic venous pressures were high. In addition,
elevated access recirculation also prompted referral for fis-
tulagraphy. Invasive imaging was not routinely performed
for asymptomatic stenosis.
When a prosthetic access occluded, it was reopened
using either mechanical or surgical thrombectomy. If me-
chanical thrombectomy was used, balloon angioplasty of
the culprit stenosis was attempted. If surgical thrombec-
tomy was used, surgical repair of the underlying lesion was
attempted. Occluded tAVF were either abandoned or re-
opened using mechanical thrombectomy. In the latter case,
percutaneous angioplasty or surgical revision was at-
tempted.
Statistical analysis was performed using the statistical
analysis system (SAS). Summary results for were presented
as mean  standard deviation continuous variables and as
frequency (percent) for categorical variables. Two-group
comparisons were assessed by the independent samples t
test or the Wilcoxon rank sum test, as appropriate of
continuous variables and by 2 test or Fisher exact test for
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abandonment rates at each time point were calculated by
the life table method as outlined by the Society of Vascular
Surgery Ad Hoc Committee on Reporting Standards39
(Appendix IV to XI, online only). Survival differences were
tested with the log rank test.
Primary patency was defined as time of access place-
ment until first thrombosis or any intervention designed to
maintain patency.18 Follow-up for primary patency rate
calculations ended when the graft was confirmed to require
intervention, thrombosed, or last known to be patent
(whichever was shorter). Placement of a dialysis catheter in
a patient with a presumably functioning graft, death, or
kidney transplantation were additional endpoints for termi-
nation of patency. Secondary patency was defined as the
interval from the time of access placement until access
abandonment.18 Secondary patency rate calculations
ended when the patient had a new surgical dialysis access
placed. Multivariate Cox proportional hazard models were
evaluated to assess association of type of vein (BVT vs CVT)
and type of surgery (AVG vs tAVF) on the hazard of
primary or secondary access failure while controlling for
other independent predictor variables. To search for a final
model, we used the stepwise selection.
RESULTS
During the 6.5-year study period, 190 upper arm tAVF
were constructed in 190 limbs of 190 patients. There were
119 BVT and 71 CVT procedures. During that time pe-
riod, 828 upper arm AVG and 81 antecubital nontrans-
posed brachiocephalic AVF were placed. One hundred and
sixty-four primary upper arm AVG performed during the
period of 1999 to 2001 in 164 limbs in 139 patients were
chosen for our comparative analysis.
The etiology of ESRD in our tAVF patient cohort was
hypertensive nephropathy in 25.8%, diabetic nephropathy
in 39.5%, and autoimmune disease in 9.5% of the patients.
In 17.4%, other causes such as polycystic kidney disease and
contrast nephropathy were culprit, and in 7.8%, the etiol-
ogy of renal failure was unknown.
There was no significant difference in the mean age,
gender, race, history of previous access, and diabetes be-
tween the BVT and CVT cohorts. On average, basilic veins
used for BVT were larger than cephalic veins used for CVT
(4.4 mm vs 3.8 mm, respectively, P  .001). A similar
proportion of BVT and CVT patients were undergoing
hemodialysis at the time of access construction (59% BVT,
65% CVT, P  NS). Finally, 50% of BVT and 55% of CVT
patients had a history of previous upper torso dialysis cath-
eters (P  NS) (Table I A).
The mean age of the tAVF group was significantly
lower than the mean age of the AVG group: 63 vs 67 years
(P  .019). There were a significantly higher percent of
men in the tAVF group compared with the AVG group:
63% vs 48% (P  .004). The percent of African Americans
(AA) in the tAVF group was significantly lower than in the
AVG group: 25% vs 38% (P .006). Finally, fewer patients
in the tAVF group had a history of previous access proce-dures: 19% vs 32% (P  .007). There was no significant
group difference in the percent of patients with diabetes
(Table I B).
There was no significant difference in the thirty day
mortality, grade 2 wound infection, 24 hour thrombosis,
grade 3 postoperative hemorrhage, or grade 3 steal be-
tween the BVT and CVT groups (Table II A). Mean
follow-up was 28months. The primary patency of BVTwas
71% and 52% at 1 year and 5 years, respectively. The
primary patency of CVT was 56% and 40% at 1 year and 5
years, respectively (P  NS) (Fig 1, A). The secondary
patency of BVT was 76% and 62% at 1 year and 5 years,
respectively. The secondary patency of CVT was 66% and
46 % at 1 year and 5 years, respectively (PNS) (Fig 1, B).
Four surgical and 22 endovascular revision procedures
were performed in the BVT and CVT groups to maintain
secondary patency; 92% of BVT and 91% of CVT required
no revisions (P  NS). Bivariate analysis revealed that vein
type was not associated with any difference in primary and
secondary patency across subgroups defined by age, gen-
der, race, and diabetic status (Appendix II and III, online
Table I A. Patient characteristics according to tAVF type
BVT (%) CVT (%) P-value
Mean age  SD 64  19 60  16 .161
Male gender 79 (66) 41 (58) .277
AA race 30 (25) 17 (24) .999
Diabetes (grade 1-3) 54 (48) 40 (56) .295
Previous UE access 21 (18) 16 (23) .451
Mean vein diameter (mm) 4.4  0.99 3.8  0.83 .001
On dialysis 70 (59) 46 (65) .445
Previous catheter 60 (50) 39 (55) .553
SD, Standard deviation; AA, African-American; UE, upper extremity.
Table I B. Patient characteristics according to access
type
tAVF (%) AVG (%) P-value
Mean age  SD 63  18 67  16 .019
Male gender 120 (63) 78 (48) .004
AA race 47 (25) 63 (38) .006
Diabetes (grade 1-3) 97 (51) 74 (45) .287
Previous UE access 37 (19) 53 (32) .007
SD, Standard deviation; AA, African-American; UE, upper extremity.
Table II A. Mortality and complications according to
tAVF type
BVT (%) CVT (%) P-value
30 day mortality 5 (4.2) 0 (0.0) .159
Infection (grade 2) 3 (2.5) 0 (0.0) .294
24 hour thrombosis 0 (0.0) 1 (1.4) .374
Bleeding (grade 3) 6 (5.0) 1 (1.4) .260
Steal (grade 3) 3 (2.5) 3 (4.2) .673only). Multivariate analysis revealed that being dialysis de-
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confidence interval [CI] 1.13 to 3.47, P .017) and a
history of previous upper arm access (HR 1.85, 95% CI
1.10 to 3.14, P  .021) increased the risk of primary
failure. History of previous upper torso catheter increased
the risk of secondary failure (HR 2.17, 95% CI 1.29 to
3.65, P .003). Vein type was not a significant predictor of
access patency.
Autogenous BVT and CVT were combined into one
tAVF group and compared with the AVG cohort. The
thirty-day mortality rate was 2.6% in patients with tAVF
and 5.5% in those with AVG (P  .151). There was a
significantly lower risk of grade 2 wound infection in the
tAVF group compared with AVG group: 1.6% vs 10.4% (P
 .001). There was no significant difference in 24-hour
thrombosis rates between the groups. There was a higher,
albeit not statistically significant, incidence in postoperative
bleeding requiring re-operation in the tAVF group: 3.7% vs
0.6% (P  .07). Finally, there was a significantly decreased
incidence of grade 3 steal in the tAVF group: 3.2% vs 8.5%,
(P  .037) (Table II B).
The primary patency rate for the tAVF cohort was 65%
Fig 1. A, Kaplan-Meier curves of primary patency for BVT and
CVT. B, Kaplan-Meier curves of secondary patency for BVT and
CVT.and 48% at 1 year and 5 years, respectively. The primarypatency rate for the AVG cohort was 34% and 14% at 1 year
and 5 years, respectively. Primary patency in the tAVF
group was significantly higher than for the AVG group (P
 .001) (Fig 2, A).
The secondary patency rate for the tAVF cohort was
72% and 57% at 1 year and 5 years, respectively. The
secondary patency for the AVG group was 63% and 17% at
1 year and 5 years, respectively. Secondary patency in the
tAVF group was significantly higher than in the AVG group
(P  .001) (Fig 2, B).
In the tAVF cohort, there were four surgical and 22
Table II B. Mortality and complications according to
access type
tAVF (%) AVG (%) P-value
30 day mortality 5 (2.6) 9 (5.5) .151
Infection (grade 2) 3 (1.6) 17 (10.4) .001
24 hour thrombosis 1 (0.5) 2 (1.2) .598
Bleeding (grade 3) 7 (3.7) 1 (0.6) .070
Steal (grade 3) 6 (3.2) 14 (8.5) .037
Fig 2. A, Kaplan-Meier curves of primary patency for tAVF and
AVG. B, Kaplan-Meier curves of secondary patency for tAVF and
AVG.endovascular revision procedures performed during the
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endovascular revision procedures were performed. Among
the tAVF procedures, 9% required one or more revisions to
maintain secondary patency, compared with 51% in the
AVG group (P  .001). When a revision was necessary, a
mean and median of 1.5 and 1 revision in the tAVF group
vs 2.8 and 3 in the AVG group were performed, respec-
tively.
Sub-group analysis of AA patients, patients greater than
80 years old and those with diabetes revealed that tAVF had
significantly higher primary patency rates compared with
AVG (P  .004, P  .020, and P  .001, respectively).
Multivariate analysis revealed that presence of tAVF de-
creased the risk for primary (HR 0.40, 95%CI 0.30 to 0.54,
P .001) and secondary failure (HR 0.49, 95% CI 0.36 to
0.67, P  .001). History of previous access increased the
risk of primary (HR 1.76, 95% CI 1.30 to 2.39, P  .001)
and secondary failure (HR 1.75, 95% CI 1.27 to 2.42, P
.001). Age, gender, diabetes, and race did not significantly
influence primary or secondary failure.
DISCUSSION
In 1976, Dagher was the first to describe the use of the
elevated brachial-basilic upper arm AV fistula,7 also termed
basilic vein transposition (BVT). Although BVT has been
described to have excellent patency rates10-13,19-21 some
authors report less spectacular results.14,15 We evaluated
our experience with BVT and CVT procedures to compare
our patency rates with those published in the literature and
determine whether using one type of vein is superior.
Our BVT primary and secondary patency rates compare
favorably with published patency rates.10,12,14,19-23 The
BVT and CVT groups were well matched with respect to
demographics with the exception of the fact that basilic
veins were on the average somewhat larger. Analysis re-
vealed that there was no significant difference between
these procedures in terms of complication rates, patency, or
the number and type of revisions performed. Bivariate and
multivariate analysis confirmed that vein type did not affect
patency rates. These findings are not surprising since both
BVT and CVT are based on deeper veins less likely to have
been violated by venipuncture and both procedures are of
similar operative complexity.
We found that dialysis dependence at the time of fistula
placement negatively affects primary patency rates of the
BVT and CVT procedures. This finding likely reflects the
fact that prolonged dialysis leads to eventual obliteration of
central venous outflow and consequent fistula failure. Our
finding that previous upper torso catheters negatively affect
secondary patency has been demonstrated by others and is,
likewise, related to catheter induced central venous outflow
obliteration.24
Comparison studies of BVT and AVG reveal results
that range from demonstration of superior patency of BVT
over AVG12,21 to reports of similar patency rates22,25 be-
tween the two types of access procedures. To address this
controversy, we elected to compare our tAVF cohort with a
sample of upper arm AVG. Our AVG cohort represented atypical group of AVG patients but was not case matched
with the tAVF cohort. The patients in the tAVF group were
significantly younger, a higher proportion was male, fewer
were African American, and fewer patients had a history of
previous access operations compared with the patients in
the AVG group (Table I B). These differences parallel
findings from multiple other studies.3,25-29
In our series, tAVF had a lower rate of grade 2
infections, more grade 3 postoperative bleeding, and less
grade 3 steal than the AVG cohort. This has been noted
by others.9,12,14,20,25,30-33 Our tAVF patency rates are
much higher than those of AVG (Fig 2). Comparison of
tAVF and AVG in the literature reveals that in many12,21
but not all22,25 series, tAVF had improved primary and
secondary patency compared with the AVG cohorts.
Notwithstanding lower access patency rates, patients
who received AVG in our study required significantly
more interventions to maintain secondary patency com-
pared with those in the tAVF group. This has been
described by others.3,25,34 In fact, one author described
up to 91% higher incidence of revisions for AVG com-
pared with native AVF22.
Multivariate analysis of our data revealed that history of
previous access operations increased the risk for primary
and secondary failure. History of previous access surgery
may be linked to worse outcomes 20,22 because of its effect
on arterial and venous anatomy and possibly due to other
poorly defined patient factors such as predisposition to an
aggressive neointimal hyperplastic response.
In our series, gender, history of diabetes, and patient
age did not exert an effect on access patency. Some authors
have noted that female gender correlates with decreased
fistula maturation and patency rate.3,35,36 Although there is
evidence that diabetes decreases patency of radiocephalic
AVF, it does not correlate with increased risk for failure of
transposed upper arm AVF.3,11 Older age has been associ-
ated with decreased AVF patency37,38 and age greater than
60 years has been noted to correlate with diminished BVT
maturation in one series.14 However, in another large
series, age did not affect BVT patency.22
The main limitation of this study is that it is a retrospec-
tive review. Certainly this allows for introduction of bias
and confounding variables that may affect our conclusions.
Another limitation of the study is that the exact reason
behind the choice to perform a given operation was not
known and, therefore, surgeon bias could not be well
controlled. Finally, the AVG group was not matched with
the tAVF group and there were significant differences be-
tween these patients. Therefore, patency and subgroup
comparison of these groups is subject to bias.
Although the most recent DOQI Guidelines edition
recommends utilization of BVT, there are conflicting re-
ports regarding its performance. Our series of 119 BVT
procedures suggests that this arteriovenous fistula has ex-
cellent patency rates. Autogenous BVT perform similarly to
CVT and both outperform AVG. These data support the
conclusion that patients who are not candidates for simple
radiocephalic or brachiocephalic AVF but who are candi-
JOURNAL OF VASCULAR SURGERY
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should always be offered the latter procedure. Upper arm
AVG should be utilized only in those patients in whom
tAVF construction is not possible.
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Operative technique In the operating room, the major-
ity of procedures were performed under local anesthesia
with sedation. For patients who did not tolerate local
anesthesia, general anesthesia was required. The basilic or
cephalic vein was exposed and dissected from 1 to 2 cm
distal to the antecubital fossa to the proximal axilla or
shoulder, respectively. All branches were controlled with
silk suture and the vein was divided distally. The brachial
artery was then exposed immediately proximal to the ante-
cubital fossa and the vein was tunneled superficially to lie
next to the brachial artery. In most CVT procedures, the
brachial artery was exposed through a separate, medial
antecubital incision. After administration of systemic or local
heparin, an end to side anastomosis was constructed between
the transposed vein and brachial artery. The use of systemic
heparin was based on surgeon preference. When systemic
heparin was given, it was always reversed with protamine. For
upper arm AVG procedures, the brachial artery and axillary
vein were exposed through distal and proximal medial upper
arm incisions, respectively. Venous and arterial anastomoses
were constructed in an end to side fashion. The majority of
patients were discharged the same day. Patients who were felt
to require observation due to comorbidities or other extenu-
ating circumstances were admitted to the hospital and were
discharged on the first postoperative day.
Appendix II. (online only) Forest plot for primary
patency of BVT and CVT
Appendix III. (online only) Forest plot of secondary
patency of BVT and CVTAppendix IV. (online only) Life table for primary
patency for BVT
Patency
time
Effective
sample
size Failed Censored
Primary
patency
Standard
error
0 115.5 13 7 100.00% 0
3 98 11 2 88.74% 0.029
6 85 4 2 78.78% 0.038
9 76 4 8 75.08% 0.041
12 65 4 6 71.12% 0.043
15 54 2 8 66.75% 0.046
18 46 1 4 64.28% 0.047
21 40.5 1 5 62.88% 0.048
24 34.5 1 5 61.33% 0.050
27 30 0 2 59.55% 0.051
30 29 0 0 59.55% 0.051
33 27 1 4 59.55% 0.051
36 22.5 0 3 57.34% 0.053
39 19.5 0 3 57.34% 0.053
42 17.5 0 1 57.34% 0.053
45 17 0 0 57.34% 0.053
48 15.5 0 3 57.34% 0.053
51 11 1 6 57.34% 0.053
54 6.5 0 1 52.13% 0.069
57 5 0 2 52.13% 0.069
60 2 0 4 52.13% 0.069
Appendix V. (online only) Life table for secondary
patency for BVT
Patency
time Failed Censored
Effective
sample
size
Secondary
patency
Standard
error
0 12 6 116 100.00% 0
3 8 3 99.5 89.66% 0.028
6 6 1 89.5 82.45% 0.035
9 1 8 79 76.92% 0.039
12 2 7 70.5 75.95% 0.040
15 2 7 61.5 73.79% 0.042
18 2 4 54 71.39% 0.044
21 2 6 47 68.75% 0.046
24 0 8 38 65.82% 0.048
27 0 2 33 65.82% 0.048
30 1 0 32 65.82% 0.048
33 1 4 29 63.77% 0.051
36 0 3 24.5 61.57% 0.054
39 0 3 21.5 61.57% 0.054
42 0 2 19 61.57% 0.054
45 0 0 18 61.57% 0.054
48 0 3 16.5 61.57% 0.054
51 0 6 12 61.57% 0.054
54 0 2 8 61.57% 0.054
57 0 2 6 61.57% 0.054
60 0 5 2.5 61.57% 0.054
Appendix VI. (online only) Life table for primary
patency for CVT
Patency
time
Effective
sample
size Failed Censored
Secondary
patency
Standard
error
0 69.5 9 3 100.00% 0
3 58.5 11 1 87.05% 0.040
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patency for CVT Continued.
Patency
time
Effective
sample
size Failed Censored
Secondary
patency
Standard
error
6 45 5 4 70.68% 0.055
9 36.5 4 3 62.83% 0.059
12 29 0 4 55.94% 0.061
15 25 1 4 55.94% 0.061
18 21.5 0 1 53.71% 0.063
21 19 0 4 53.71% 0.063
24 16.5 2 1 53.71% 0.063
27 13.5 0 1 47.20% 0.070
30 11.5 0 3 47.20% 0.070
33 9 0 2 47.20% 0.070
36 7 1 2 47.20% 0.070
39 5 0 0 40.45% 0.086
42 4.5 0 1 40.45% 0.086
45 4 0 0 40.45% 0.086
48 3.5 0 1 40.45% 0.086
51 3 0 0 40.45% 0.086
54 3 0 0 40.45% 0.086
57 3 0 0 40.45% 0.086
60 1.5 0 3 40.45% 0.086
Appendix VII. (online only) Life table for secondary
patency for CVT
Patency
time
Effective
sample
size Failed Censored
Secondary
patency
Standard
error
0 69 5 4 100.00% 0
3 61.5 7 1 92.75% 0.031
6 52 7 4 82.20% 0.046
9 41 3 4 71.13% 0.056
12 33 1 6 65.93% 0.059
15 26 1 6 63.93% 0.060
18 21.5 0 1 61.47% 0.063
21 19 0 4 61.47% 0.063
24 16.5 2 1 61.47% 0.063
27 13.5 0 1 54.02% 0.074
30 11.5 0 3 54.02% 0.074
33 9 0 2 54.02% 0.074
36 7 1 2 54.02% 0.074
39 5 0 0 46.30% 0.095
42 4.5 0 1 46.30% 0.095
45 4 0 0 46.30% 0.095
48 3.5 0 1 46.30% 0.095
51 3 0 0 46.30% 0.095
54 3 0 0 46.30% 0.095
57 3 0 0 46.30% 0.095
60 1.5 0 3 46.30% 0.095
Appendix VIII. (online only) Life table for primary
patency for AVG
Patency
time
Effective
sample
size Failed Censored
Primary
patency
Standard
error
0 155.5 57 17 100.00% 0
3 88 17 4 63.34% 0.038
6 67 12 4 51.11% 0.041
9 51.5 10 3 41.95% 0.04112 38.5 7 3 33.81% 0.040Appendix VIII. (online only) Life table for primary
patency for AVG
Patency
time
Effective
sample
size Failed Censored
Primary
patency
Standard
error
15 29.5 3 1 27.66% 0.039
18 25.5 3 1 24.85% 0.038
21 22 0 0 21.92% 0.037
24 21.5 3 1 21.92% 0.037
27 18 1 0 18.87% 0.036
30 16.5 1 1 17.82% 0.035
33 15 0 0 16.74% 0.035
36 14.5 2 1 16.74% 0.035
39 11.5 0 1 14.43% 0.033
42 9 0 4 14.43% 0.033
45 6.5 0 1 14.43% 0.033
48 5 0 2 14.43% 0.033
51 3 0 2 14.43% 0.033
54 1.5 0 1 14.43% 0.033
57 1 0 0 14.43% 0.033
60 0.5 0 1 14.43% 0.033
Appendix IX. (online only) Life table for secondary
patency for AVG
Patency
time Failed Censored
Effective
sample
size
Secondary
patency
Standard
error
0 31 17 155.5 100.00% 0
3 9 5 113.5 80.06% 0.032
6 3 4 100 73.72% 0.035
9 13 4 93 71.50% 0.036
12 10 4 76 61.51% 0.040
15 7 1 63.5 53.42% 0.042
18 8 3 54.5 47.53% 0.043
21 6 1 44.5 40.55% 0.043
24 4 2 37 35.08% 0.042
27 3 0 32 31.29% 0.042
30 2 1 28.5 28.36% 0.041
33 3 0 26 26.37% 0.040
36 1 1 22.5 23.32% 0.039
39 1 1 20.5 22.29% 0.039
42 0 4 17 21.20% 0.038
45 0 1 14.5 21.20% 0.038
48 1 3 12.5 21.20% 0.038
51 1 3 8.5 19.50% 0.039
54 0 3 4.5 17.21% 0.040
57 0 1 2.5 17.21% 0.040
60 0 2 1 17.21% 0.040
Appendix X. (online only) Life table for primary
patency for tAVF
Patency
time Failed Censored
Effective
sample
size
Secondary
patency
Standard
error
0 22 10 185 100.00% 0
3 22 3 156.5 88.11% 0.023
6 9 6 130 75.72% 0.031
9 8 11 112.5 70.48% 0.034
12 4 10 94 65.47% 0.036
15 3 12 79 62.68% 0.037
18 1 5 67.5 60.30% 0.038
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July 200799.e3 Woo et alAppendix X. (online only) Life table for primary
patency for tAVF Continued.
Patency
time Failed Censored
Effective
sample
size
Secondary
patency
Standard
error
21 1 9 59.5 59.41% 0.038
24 3 6 51 58.41% 0.039
27 0 3 43.5 54.97% 0.041
30 0 3 40.5 54.97% 0.041
33 1 6 36 54.97% 0.041
36 1 5 29.5 53.45% 0.043
39 0 3 24.5 51.64% 0.045
42 0 2 22 51.64% 0.045
45 0 0 21 51.64% 0.045
48 0 4 19 51.64% 0.045
51 1 6 14 51.64% 0.045
54 0 1 9.5 47.95% 0.055
57 0 2 8 47.95% 0.055
60 0 7 3.5 47.95% 0.055
Appendix XI. (online only) Life table for secondary
patency for tAVF
Patency
Time Failed Censored
Effective
sample
size
Secondary
patency
Standard
error0 17 10 185 100.00% 0Appendix XI. (online only) Life table for secondary
patency for tAVF Continued.
Patency
Time Failed Censored
Effective
sample
size
Secondary
patency
Standard
error
3 15 4 161 90.81% 0.021
6 13 5 141.5 82.35% 0.028
9 4 12 120 74.78% 0.032
12 3 13 103.5 72.29% 0.033
15 3 13 87.5 70.20% 0.034
18 2 5 75.5 67.79% 0.036
21 2 10 66 65.99% 0.037
24 2 9 54.5 63.99% 0.039
27 0 3 46.5 61.65% 0.040
30 1 3 43.5 61.65% 0.040
33 1 6 38 60.23% 0.042
36 1 5 31.5 58.64% 0.044
39 0 3 26.5 56.78% 0.046
42 0 3 23.5 56.78% 0.046
45 0 0 22 56.78% 0.046
48 0 4 20 56.78% 0.046
51 0 6 15 56.78% 0.046
54 0 2 11 56.78% 0.046
57 0 2 9 56.78% 0.046
60 0 8 4 56.78% 0.046
